| Brain regions | Control group (n = 7–9) | Unsusceptible group (n = 8–11) | Susceptible group (n = 16–20) | p |
---|---|---|---|---|---|
D2L | PFC | 1 ± 0.19 | 1.44 ± 0.24 | 1.29 ± 0.17 | 0.453 |
ST | 1 ± 0.16 | 1.18 ± 0.15 | 1.10 ± 0.09 | 0.695 | |
AMY | 1 ± 0.17 | 1.17 ± 0.16 | 1.65 ± 0.16* | 0.006 | |
HIP | 1 ± 0.22 | 1.39 ± 0.32 | 0.96 ± 0.13 | 0.307 | |
D2S | PFC | 1 ± 0.16 | 1.04 ± 0.19 | 1.02 ± 0.14 | 0.988 |
ST | 1 ± 0.17 | 0.77 ± 0.10 | 0.91 ± 0.08 | 0.503 | |
AMY | 1 ± 0.11 | 1.08 ± 0.23 | 1.77 ± 0.17*†| 0.009 | |
HIP | 1 ± 0.19 | 0.70 ± 0.09 | 1.14 ± 0.09 | 0.058 | |
Total DARPP-32 | PFC | 1 ± 0.14 | 1.38 ± 0.16 | 1.16 ± 0.11 | 0.246 |
ST | 1 ± 0.15 | 0.81 ± 0.13 | 0.88 ± 0.11 | 0.719 | |
AMY | 1 ± 0.18 | 1.23 ± 0.14 | 0.93 ± 0.08 | 0.191 | |
HIP | 1 ± 0.28 | 1.02 ± 0.17 | 0.60 ± 0.06 | 0.071 | |
p-DARPP-32 Thr34 | PFC | 1 ± 0.07 | 1.15 ± 0.12 | 1.33 ± 0.09 | 0.113 |
ST | 1 ± 0.11 | 1.15 ± 0.14 | 0.98 ± 0.07 | 0.475 | |
AMY | 1 ± 0.14 | 1.31 ± 0.14 | 1.42 ± 0.13 | 0.185 | |
HIP | 1 ± 0.23 | 0.93 ± 0.13 | 0.86 ± 0.07 | 0.781 | |
p-DARPP-32 Thr75 | PFC | 1 ± 0.08 | 1.20 ± 0.11 | 1.09 ± 0.06 | 0.349 |
ST | 1 ± 0.14 | 0.97 ± 0.09 | 0.96 ± 0.07 | 0.976 | |
AMY | 1 ± 0.02 | 0.70 ± 0.02* | 0.77 ± 0.04* | 0.002 | |
HIP | 1 ± 0.13 | 1.11 ± 0.13 | 1.05 ± 0.13 | 0.899 |